IMMU - Immunomedics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
19.00
-0.35 (-1.78%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close19.35
Open19.52
Bid18.68 x 1400
Ask19.35 x 2200
Day's Range18.89 - 19.68
52 Week Range11.59 - 22.22
Volume1,238,385
Avg. Volume2,223,667
Market Cap4.037B
Beta (5Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer

    Prescription Drug User Fee Act (PDUFA) target action date set for June 2, 2020 MORRIS PLAINS, N.J., Dec. 26, 2019 -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the.

  • GlobeNewswire

    Immunomedics Announces Closing of Public Offering of Common Stock

    The total number of shares of common stock sold was 16,428,572, composed of 14,285,715 shares of common stock initially offered and an additional 2,142,857 shares of common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, in each case at a public offering price of $17.50 per share. The total net proceeds from the offering for Immunomedics are estimated to be approximately $272 million, after deducting underwriting discounts and commissions but before deducting other estimated offering expenses payable by the Company.

  • GlobeNewswire

    Immunomedics Announces Pricing of Public Offering of Common Stock

    In addition, Immunomedics has granted the underwriters a 30-day option to purchase up to 2,142,857 additional shares of common stock. Immunomedics intends to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes. Goldman Sachs & Co. LLC, BofA Securities, Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the offering.

  • GlobeNewswire

    Immunomedics Announces Proposed Public Offering of Common Stock

    In addition, Immunomedics expects to grant the underwriters a 30-day option to purchase up to an aggregate of an additional $37,500,000 of shares of common stock sold in connection with the offering at the public offering price. Immunomedics intends to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes. Goldman Sachs & Co. LLC, BofA Securities, Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the offering.

  • GlobeNewswire

    Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan

    MORRIS PLAINS, N.J., Dec. 03, 2019 -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug.

  • GlobeNewswire

    Immunomedics to Present at Upcoming Healthcare Conferences

    MORRIS PLAINS, N.J., Nov. 13, 2019 -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug.

  • GlobeNewswire

    Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update

    TROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients First NSCLC Patient Dosed in Trop-2-Enriched TROPiCS-03 Study BLA.

  • GlobeNewswire

    Immunomedics to Report Third Quarter 2019 Results and Host Conference Call and Webcast on October 30, 2019

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, October 30, 2019 at 5:00 p.m. Eastern Time to discuss financial results for the third quarter of 2019 and provide a corporate update. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days.

  • ACCESSWIRE

    SHAREHOLDER REMINDER: Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders; The Law Offices of Timothy L. Miles Encourages Immunomedics Shareholders to Contact the Firm

    HENDERSONVILLE, TN / ACCESSWIRE / October 9, 2019 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 18 years, reminds shareholders that purchasers ...

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, Inc. following a class action complaint that was filed against Healthcare Services on March 22, 2019.

  • GlobeNewswire

    Immunomedics to Present at the 2019 Cantor Global Healthcare Conference  

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 10:05 a.m. Eastern Time in New York, N.Y. A live audio webcast of the presentation will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at the conference.

  • GlobeNewswire

    Immunomedics Provides Corporate Update

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today presented at the European Society for Medical Oncology (ESMO) Annual Congress interim data from the 100-patient cohort of cisplatin-eligible patients of the Company’s TROPHY-U-01 open-label Phase 2 study. In this interim report, sacituzumab govitecan produced an overall response rate (ORR) of 29 percent in 35 patients with metastatic urothelial cancer (mUC) who have relapsed or are refractory to immune checkpoint inhibitors (CPI) and platinum-based chemotherapy.

  • ACCESSWIRE

    SHAREHOLDER ALERT: Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders; The Law Offices of Timothy L. Miles Encourages Immunomedics Shareholders to Contact the Firm

    HENDERSONVILLE, TN / ACCESSWIRE / September 16, 2019 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 18 years, announces that purchasers of ...

  • GlobeNewswire

    Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host an Investor Event on Saturday, September 28, 2019 at 6:30 p.m. Central European Summer Time in Barcelona, Spain, during the Congress 2019. The event will feature presentations by key opinion leaders including Scott Tagawa, M.D., MS, Richard A. Stratton Associate Professor in Hematology & Oncology, Associate Professor of Medicine & Urology, Weill Cornell Medicine, and Associate Attending Physician, NewYork-Presbyterian – Weill Cornell Medical Center, who will present the interim results from TROPHY-U-01 at the Congress. Cora N. Sternberg, M.D., FACP, Clinical Director, Englander Institute for Precision Medicine and Professor of Medicine in Hematology & Oncology, Weill Cornell Medicine and NewYork-Presbyterian will discuss the implications of these data in an evolving metastatic urothelial cancer landscape.

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire is investigating certain officers and directors of MGT Capital Investments (Other OTC: MGTI), First American Financial Corporation (FAF), Immunomedics, Inc. (IMMU), and AAC Holdings, Inc. (AAC) on behalf of long-term stockholders. Bragar Eagel and Squire is investigating certain officers and directors of MGT Capital Investments following a class action complaint that was filed against MGT Capital on October 9, 2018. The complaint alleges that throughout the class period, defendants made materially false and misleading statements regarding the company's business, operational and compliance policies.

  • GlobeNewswire

    Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress

    Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that its TROPHY-U-01 late-breaking abstract on interim results of sacituzumab govitecan in patients with metastatic urothelial cancer (mUC) has been selected for oral presentation at the ESMO 2019 Annual Congress, taking place from  September 27 to October 1, 2019, at the Fira Barcelona, Spain. “We look forward to presenting, for the first time, interim data for sacituzumab govitecan in metastatic urothelial cancer patients who are relapsed or refractory to platinum-based and checkpoint inhibitor therapies,” commented Dr. Behzad Aghazadeh, Executive Chairman.

  • GlobeNewswire

    Immunomedics to Participate in Upcoming Healthcare Conferences

    Live audio webcast of the fireside chats will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at these conferences.

  • GlobeNewswire

    Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update

    ASCENT Study Reached Target Patient Enrollment First Patients Dosed in TROPICS-02 Study in HR+/HER2– Metastatic Breast Cancer Trop-2-Enriched TROPICS-03 Basket Study Initiated.

  • GlobeNewswire

    Immunomedics to Report Second Quarter 2019 Results and Host Conference Call and Webcast on August 7, 2019

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, August 7, 2019 at 5:00 p.m. Eastern Time to discuss financial results for the second quarter of 2019 and provide a corporate update. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days.

  • GlobeNewswire

    Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update

    Agreement with Janssen Established to Co-Promote Balversa Sacituzumab Govitecan Licensed to Everest Medicines for Greater China and Certain Asian Countries Resubmission of.

  • GlobeNewswire

    Immunomedics To Participate In Upcoming Healthcare Conferences

    Live audio webcast of the fireside chats will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at these conferences.

  • GlobeNewswire

    Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019

    Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Thursday, May 9, 2019 at 8:00 a.m. Eastern Time to discuss financial results for the first quarter of 2019 and provide a corporate update. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days.